- Molecular NameGlycopyrrolate
- Synonymglycopyrrolate; Glycopyrronium bromide
- Weight318.437
- Drugbank_IDDB00986
- ACS_NO596-51-0
- Show 3D model
- LogP (experiment)-0.99
- LogP (predicted, AB/LogP v2.0)-1.02
- pkaN/A
- LogD (pH=7, predicted)-1.02
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)-0.48
- LogSw (predicted, AB/LogsW2.0)176.55
- Sw (mg/ml) (predicted, ACD/Labs)104.75
- No.of HBond Donors1
- No.of HBond Acceptors4
- No.of Rotatable Bonds5
- TPSA46.53
- StatusFDA approved
- Administrationoral, IV
- PharmacologyA medication of the muscarinic anticholinergic group.
- Absorption_value18.0
- Absorption (description)Rapidly absorbed (1-2 minutes) after intravenous injection
- Caco_2N/A
- Bioavailability17.0
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe in vivo metabolism of glycopyrrolate in humans has not been studied [http://www.rxlist.com/cgi/generic/glycopyrrolate_cp.htm].Studies of the metabolism of glycopyrrolate in animals indicate the major metabolic pathway to be hydroxylation of the cyclopentyl ring and oxidation of the hydroxyl group in the mandelic acid residue. These metabolites have been mainly detected in the liver and kidney
- Half life0.6~1.2 h
- Excretion85% renal, unknown amount in the bile
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySide effects include dry mouth, difficult urinating, heachaches, diarrhea and constipation. The medication also induces drowsiness or blurred vision.
- LD50 (rat)LD50=709 mg/kg
- LD50 (mouse)N/A